Cytokinetics, Incorporated (CYTK)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS23282W6057
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Cytokinetics, Incorporated, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:33. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Feb 2027 16:00 | -1.35 | — | — | Upcoming |
| 04 Nov 2026 16:00 | -1.40 | -1.37 | +2.4% | Beat |
| 06 Aug 2026 16:00 | -1.61 | -1.50 | +6.6% | Beat |
| 05 May 2026 16:00 | -1.65 | -1.67 | -1.3% | Miss |
| 24 Feb 2026 16:00 | -1.37 | -1.50 | -9.7% | Miss |
| 05 Nov 2025 16:00 | -1.57 | -1.54 | +1.6% | Beat |
| 07 Aug 2025 16:00 | -1.36 | -1.12 | +17.9% | Beat |
| 06 May 2025 16:00 | -1.36 | -1.36 | +0.2% | In line |
| 27 Feb 2025 16:00 | -1.17 | -1.26 | -7.3% | Miss |
| 06 Nov 2024 16:00 | -1.24 | -1.36 | -9.3% | Miss |
| 08 Aug 2024 16:00 | -0.91 | -1.31 | -44.4% | Miss |
| 08 May 2024 16:00 | -1.17 | -1.33 | -13.2% | Miss |
| 27 Feb 2024 16:00 | -0.95 | -1.38 | -44.9% | Miss |
| 02 Nov 2023 16:00 | -0.76 | -1.35 | -78.5% | Miss |
| 02 Aug 2023 20:00 | -1.24 | -1.34 | -7.9% | Miss |
| 04 May 2023 16:00 | -1.18 | -1.38 | -17.4% | Miss |
| 01 Mar 2023 16:00 | -1.19 | -1.45 | -21.8% | Miss |
| 03 Nov 2022 16:00 | -1.17 | -1.28 | -9.8% | Miss |
| 04 Aug 2022 16:00 | -1.01 | -0.23 | +77.3% | Beat |
| 04 May 2022 16:00 | -0.94 | -1.02 | -9.1% | Miss |
| 24 Feb 2022 16:00 | -0.84 | -0.36 | +57.4% | Beat |
| 03 Nov 2021 16:00 | -0.77 | -0.95 | -24.1% | Miss |
| 05 Aug 2021 16:00 | -0.66 | -0.86 | -29.6% | Miss |
| 06 May 2021 16:00 | -0.60 | -0.66 | -10.2% | Miss |
| 25 Feb 2021 16:00 | -0.46 | -0.62 | -34.8% | Miss |
| 04 Nov 2020 16:00 | -0.34 | -0.05 | +85.2% | Beat |
| 06 Aug 2020 16:00 | -0.57 | -0.68 | -19.6% | Miss |
| 06 May 2020 17:00 | -0.51 | -0.66 | -28.9% | Miss |
| 03 Mar 2020 16:00 | -0.44 | -0.52 | -18.2% | Miss |
| 31 Oct 2019 16:00 | -0.49 | -0.50 | -1.6% | Miss |
| 08 Aug 2019 16:00 | -0.50 | -0.56 | -12.9% | Miss |
| 09 May 2019 16:00 | -0.47 | -0.54 | -14.9% | Miss |
| 21 Feb 2019 16:00 | -0.52 | -0.48 | +7.3% | Beat |
| 01 Nov 2018 16:00 | -0.52 | -0.40 | +22.8% | Beat |
| 26 Jul 2018 16:00 | -0.51 | -0.51 | -0.4% | In line |
| 26 Apr 2018 16:00 | -0.58 | -0.56 | +3.5% | Beat |
| 15 Feb 2018 16:00 | -0.74 | -0.75 | -1.4% | Miss |
| 26 Oct 2017 16:00 | -0.62 | -0.60 | +3.9% | Beat |
| 02 Aug 2017 16:00 | -0.60 | -0.60 | +0.4% | In line |
| 27 Apr 2017 16:00 | -0.61 | -0.62 | -2.2% | Miss |
| 16 Feb 2017 16:00 | 0.21 | 0.16 | -23.8% | Miss |
| 27 Oct 2016 16:00 | -0.28 | 0.74 | +360.6% | Beat |
| 28 Jul 2016 16:00 | -0.38 | -0.29 | +23.3% | Beat |
| 28 Apr 2016 16:00 | -0.34 | -0.31 | +9.9% | Beat |
| 16 Feb 2016 16:00 | -0.32 | -0.24 | +25.4% | Beat |
| 29 Oct 2015 16:00 | -0.30 | -0.23 | +24.3% | Beat |
| 29 Jul 2015 16:00 | -0.26 | -0.27 | -2.9% | Miss |
| 30 Apr 2015 16:00 | -0.12 | -0.23 | -95.7% | Miss |
| 12 Feb 2015 16:00 | -0.17 | 0.23 | +235.3% | Beat |
| 30 Oct 2014 16:00 | -0.25 | -0.16 | +36.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 88M | +376.6% | -785M | -891.6% | -6.54 | -24.3% | -534.8M |
| 2024 | 18.5M | +145.3% | -589.5M | -3,191.1% | -5.26 | +3.5% | -399.8M |
| 2023 | 7.5M | -92.0% | -526.2M | -6,988.6% | -5.45 | -25.9% | -415.7M |
| 2022 | 94.6M | — | -389M | -411.2% | -4.33 | — | -310.9M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 63.40 | 64.96 | 53.55 | 55.45 | -11.98% | 26,056,270 | |
| Oct 2026 | 65.73 | 67.27 | 59.79 | 62.99 | -4.43% | 38,079,900 | |
| Sep 2026 | 69.85 | 76.81 | 64.25 | 65.91 | -7.05% | 42,748,400 | |
| Aug 2026 | 76.69 | 81.77 | 69.31 | 70.91 | -8.06% | 41,667,300 | |
| Jul 2026 | 85.02 | 87.93 | 76.96 | 77.13 | -9.46% | 38,626,600 | |
| Jun 2026 | 76.09 | 88.31 | 66.63 | 85.19 | +10.98% | 51,541,200 | |
| May 2026 | 63.97 | 80.20 | 62.92 | 76.76 | +19.99% | 72,374,100 | |
| Apr 2026 | 66.55 | 68.71 | 58.65 | 63.97 | -2.94% | 34,949,900 | |
| Mar 2026 | 61.62 | 67.11 | 58.43 | 65.91 | +5.93% | 46,152,100 | |
| Feb 2026 | 62.10 | 70.39 | 60.05 | 62.22 | -1.54% | 35,366,800 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 (opens in a new tab) 09 Nov 2026 12:30
- FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week (opens in a new tab) Stocktwits · 09 Nov 2026 10:23
- Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026 (opens in a new tab) Benzinga · 09 Nov 2026 08:33
- Cytokinetics, Incorporated 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 08 Nov 2026 20:07
- Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 (opens in a new tab) Benzinga · 05 Nov 2026 17:55
- Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says (opens in a new tab) MT Newswires · 05 Nov 2026 17:18
- Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 17:02
- Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 (opens in a new tab) Benzinga · 05 Nov 2026 15:16
- Cytokinetics, Incorporated Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 05 Nov 2026 13:30
- Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data (opens in a new tab) Simply Wall St. · 05 Nov 2026 10:11
- How MYQORZO Adoption Will Impact Cytokinetics (CYTK) Stock (opens in a new tab) Simply Wall St. · 05 Nov 2026 06:14
- Cytokinetics Inc (CYTK) (Q3 2026) Earnings Call Highlights: Micorzo Launch Surges with 76% ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 05:19
- Cytokinetics Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 05 Nov 2026 02:14
- Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 04 Nov 2026 23:44
- Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates (opens in a new tab) Zacks · 04 Nov 2026 21:10
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 56.16 USD
- Market cap
- 7.8B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Thin interest cover: operating profit is only -5.9× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -13.22× | Weak | 14.16× |
| Price / book | -24.35× | Weak | 3.5× |
| Price / sales | 69.08× | Weak | 3.33× |
| EV / EBITDA | -11.69× | Weak | 11.19× |
| Free cash flow yield | -5.2% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | -259.6% | Weak | 54.9% |
| Operating margin | -351.3% | Weak | 5.8% |
| Net margin | 0% | Weak | 1.2% |
| Return on assets | -27.1% | Weak | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -2.4% | Weak | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -1.95× | Good | 0.4× |
| Interest cover | -5.89× | Weak | 2.17× |
| Current ratio | 3.36× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow CYTK and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.